Desmond A Schatz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2895232/publications.pdf

Version: 2024-02-01

180 papers	17,958 citations	22153 59 h-index	14208 128 g-index
183 all docs	183 docs citations	183 times ranked	15326 citing authors

#	Article	IF	Citations
1	Cost-Effectiveness of Low-Dose Antithymocyte Globulin Versus Other Immunotherapies for Treatment of New-Onset Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 258-267.	4.4	2
2	Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study. Diabetes Care, 2022, 45, 624-633.	8.6	7
3	Improving the Prediction of Type 1 Diabetes Across Ancestries. Diabetes Care, 2022, 45, e48-e50.	8.6	7
4	A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G. Diabetes Technology and Therapeutics, 2022, 24, 573-582.	4.4	9
5	Image-Based Machine Learning Algorithms for Disease Characterization in the Human Type 1 Diabetes Pancreas. American Journal of Pathology, 2021, 191, 454-462.	3.8	19
6	Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis. Diabetes, 2021, 70, 932-943.	0.6	8
7	Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size. Diabetes, 2021, 70, 944-954.	0.6	20
8	A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet, The, 2021, 397, 208-219.	13.7	206
9	Integrative analyses of TEDDY Omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes. Genome Biology, 2021, 22, 39.	8.8	22
10	How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?. Diabetes, 2021, 70, 1021-1028.	0.6	2
11	Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. Diabetes, 2021, 70, 1123-1129.	0.6	11
12	Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science Translational Medicine, 2021, 13, .	12.4	142
13	Islet sympathetic innervation and islet neuropathology in patients with type 1 diabetes. Scientific Reports, 2021, 11, 6562.	3.3	18
14	Monogenic Diabetes and Integrated Stress Response Genes Display Altered Gene Expression in Type 1 Diabetes. Diabetes, 2021, 70, 1885-1897.	0.6	7
15	Immune Intervention in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2021, 23, S-179-S-184.	4.4	0
16	Insulin immunotherapy for pretype 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 390-396.	2.3	5
17	The influence of selection bias on identifying an association between allergy medication use and SARS-CoV-2 infection. EClinicalMedicine, 2021, 37, 100936.	7.1	6
18	Delayed diagnosis of diabetic ketoacidosis and associated mortality during the COVID â€19 pandemic. Journal of Diabetes, 2021, 13, 837-839.	1.8	0

#	Article	IF	Citations
19	Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. Diabetes Technology and Therapeutics, 2021, 23, 857-861.	4.4	28
20	Altered cellular localisation and expression, together with unconventional protein trafficking, of prion protein, PrPC, in type 1 diabetes. Diabetologia, 2021, 64, 2279-2291.	6.3	7
21	Defining a cure for type 1 diabetes: a call to action. Lancet Diabetes and Endocrinology,the, 2021, 9, 553-555.	11.4	12
22	A unified mathematical model of thyroid hormone regulation and implication for personalized treatment of thyroid disorders. Journal of Theoretical Biology, 2021, 528, 110853.	1.7	8
23	IL-6 receptor blockade does not slow Î² cell loss in new-onset type 1 diabetes. JCI Insight, 2021, 6, .	5.0	25
24	Substance Use Affects Type 1 Diabetes Pancreas Pathology: Implications for Future Studies. Frontiers in Endocrinology, 2021, 12, 778912.	3.5	0
25	Teaching Type 1 Diabetes: Creating Stakeholder Engagement in Biomedical Careers Through Undergraduate Research Curriculum. Medical Science Educator, 2020, 30, 69-73.	1.5	1
26	Temporal Analysis of Amylase Expression in Control, Autoantibody-Positive, and Type 1 Diabetes Pancreatic Tissues. Diabetes, 2020, 69, 60-66.	0.6	18
27	Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis. Diabetes, 2020, 69, 413-423.	0.6	29
28	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care, 2020, 43, 5-12.	8.6	220
29	Propelling Health Care into the Twenties. Biomedicine Hub, 2020, 5, 1-53.	1.2	9
30	A combined risk score enhances prediction of type 1 diabetes among susceptible children. Nature Medicine, 2020, 26, 1247-1255.	30.7	83
31	Use of Ecological Momentary Assessment to Measure Self-Monitoring of Blood Glucose Adherence in Youth With Type 1 Diabetes. Diabetes Spectrum, 2020, 33, 280-289.	1.0	8
32	Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 948-953.	4.4	41
33	Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine, 2020, 26, 1380-1384.	30.7	127
34	Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study. Diabetes Care, 2020, 43, 2066-2073.	8.6	41
35	Immune Intervention in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, S-141-S-148.	4.4	0
36	Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic Î² cells. JCI Insight, 2020, 5, .	5.0	34

#	Article	IF	Citations
37	Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trialâ€"Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. Diabetes, 2020, 69, 1827-1832.	0.6	23
38	Exocrine Pancreas Dysfunction in Type 1 Diabetes. Endocrine Practice, 2020, 26, 1505-1513.	2.1	18
39	An Iterative Process for Identifying Pediatric Patients With Type 1 Diabetes: Retrospective Observational Study. JMIR Medical Informatics, 2020, 8, e18874.	2.6	1
40	The Discovery and Structure of Human Insulin. Pediatric Endocrinology Reviews, 2020, 17, 131-137.	1.2	2
41	Is It Time to Prioritize Diabetes Prevention in Practice?. Journal of the American Board of Family Medicine, 2019, 32, 457-459.	1.5	7
42	Genetic risk for autoimmunity is associated with distinct changes in the human gut microbiome. Nature Communications, 2019, 10, 3621.	12.8	132
43	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019, 42, 1593-1603.	8.6	2,101
44	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 603-613.	27.0	584
45	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes, 2019, 68, 1267-1276.	0.6	80
46	Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY Study Progress Report. Diabetes Care, 2019, 42, 1051-1060.	8.6	75
47	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodiumâ€"Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	8.6	249
48	Immune Intervention in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, S-95-S-100.	4.4	2
49	Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nature Medicine, 2019, 25, 1865-1872.	30.7	161
50	Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 281-287.	8.6	80
51	Immunomodulatory activity of humanized antiâ€"IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI Insight, 2019, 4, .	5.0	23
52	Designing Online and Mobile Diabetes Education for Fathers of Children With Type 1 Diabetes: Mixed Methods Study. JMIR Diabetes, 2019, 4, e13724.	1.9	9
53	Enhanced Understanding of the Natural History of Pre-Type 1 Diabetes: Fundamental to Prevention. Pediatric Endocrinology Reviews, 2019, 16, 359-368.	1.2	0
54	Early Infant Diet and Islet Autoimmunity in the TEDDY Study. Diabetes Care, 2018, 41, 522-530.	8.6	48

#	Article	IF	Citations
55	Pancreatic Histopathology of Human Monogenic Diabetes Due to Causal Variants in KCNJ11, HNF1A, GATA6, and LMNA. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 35-45.	3.6	17
56	Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. Diabetes, 2018, 67, 146-154.	0.6	72
57	Growth hormone and insulin-like growth factor-I axis in type 1 diabetes. Growth Hormone and IGF Research, 2018, 38, 49-52.	1.1	24
58	Hospital time prior to death and pancreas histopathology: implications for future studies. Diabetologia, 2018, 61, 954-958.	6.3	5
59	Type 1 Diabetes. , 2018, , 110-115.		1
60	The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update. Current Diabetes Reports, 2018, 18, 136.	4.2	77
61	Immune Intervention for Type 1 Diabetes. Diabetes Technology and Therapeutics, 2018, 20, S-86-S-93.	4.4	0
62	Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetesâ€"The TrialNet Experience. Diabetes, 2018, 67, 1216-1225.	0.6	29
63	Understanding Pre-Type 1 Diabetes: The Key to Prevention. Frontiers in Endocrinology, 2018, 9, 70.	3.5	25
64	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves Î²-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care, 2018, 41, 1917-1925.	8.6	114
65	Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care, 2018, 41, 2026-2044.	8.6	288
66	Transition Education for Young Adults With Type 1 Diabetes: Pilot Feasibility Study for a Group Telehealth Intervention. JMIR Diabetes, 2018, 3, e10909.	1.9	11
67	Serum Trypsinogen Levels in Type 1 Diabetes. Diabetes Care, 2017, 40, 577-582.	8.6	40
68	Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice. Scientific Reports, 2017, 7, 42372.	3.3	20
69	Immune Interventions for Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2017, 19, S-74-S-81.	4.4	1
70	Type 1 diabetes mellitus. Nature Reviews Disease Primers, 2017, 3, 17016.	30.5	790
71	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 2017, 66, 241-255.	0.6	454
72	Association Between Early-Life Antibiotic Use and the Risk of Islet or Celiac Disease Autoimmunity. JAMA Pediatrics, 2017, 171, 1217.	6.2	79

#	Article	IF	Citations
73	High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes. Diabetes Care, 2017, 40, e122-e123.	8.6	6
74	Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 1891.	7.4	142
75	Intake of Energy and Protein is Associated with Overweight Risk at Age 5.5 Years: Results from the Prospective TEDDY Study. Obesity, 2017, 25, 1435-1441.	3.0	18
76	My Child Is Islet Autoantibody Positive: Impact on Parental Anxiety. Diabetes Care, 2017, 40, 1167-1172.	8.6	25
77	Tracking the Antibody Immunome in Type 1 Diabetes Using Protein Arrays. Journal of Proteome Research, 2017, 16, 195-203.	3.7	38
78	Socioeconomic Status and the Domestic Allocation of Type 1 Diabetes Care. People Living With and Inspired By Diabetes, 2017, 3, .	0.0	0
79	Immunoproteomic Profiling of Antiviral Antibodies in New-Onset Type 1 Diabetes Using Protein Arrays. Diabetes, 2016, 65, 285-296.	0.6	59
80	Reevaluation of CMSâ€™ Competitive Bidding Program. Diabetes Care, 2016, 39, 1078-1079.	8.6	3
81	Vitamin D status in youth with type 1 and type 2 diabetes enrolled in the Pediatric Diabetes Consortium (PDC) is not worse than in youth without diabetes. Pediatric Diabetes, 2016, 17, 584-591.	2.9	17
82	Immune Intervention in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, S-69-S-75.	4.4	1
83	Pancreatic duct hyperplasia/dysplasia in type 1 diabetes and pancreatic weight in individuals with and without diabetes. Reply to Kobayashi T, Aida K, Fukui T et al [letter] and Saisho Y [letter]. Diabetologia, 2016, 59, 870-872.	6.3	2
84	Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome, 2016, 4, 17.	11.1	100
85	2016 Presidential Address: Diabetes at 212Â°â€”Confronting the Invisible Disease. Diabetes Care, 2016, 39, 1657-1663.	8.6	13
86	Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. Diabetes, 2016, 65, 3765-3775.	0.6	62
87	The DIPP project: 20 years of discovery in type 1 diabetes. Pediatric Diabetes, 2016, 17, 5-7.	2.9	19
88	Diagnostic Dilemma: Clinical and Histological Abnormalities in a Hispanic Patient With Diabetes. Diabetes Care, 2016, 39, 1650-1652.	8.6	1
89	Current and future efforts toward the prevention of type 1 diabetes. Pediatric Diabetes, 2016, 17, 78-86.	2.9	19
90	Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study. Scientific Reports, 2016, 6, 27887.	3.3	31

#	Article	IF	Citations
91	Type 1 diabetes through two lenses: comparing adolescent and parental perspectives with photovoice. International Journal of Pediatric Endocrinology (Springer), 2016, 2016, 2.	1.6	6
92	Reversion of Î²-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care, 2016, 39, 1535-1542.	8.6	56
93	Educational Needs and Technological Preferences of Fathers of Youth With Type 1 Diabetes. The Diabetes Educator, 2016, 42, 209-219.	2.5	10
94	C-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes, 2016, 17, 274-280.	2.9	15
95	Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult participants in the T1D exchange clinic registry. Pediatric Diabetes, 2016, 17, 327-336.	2.9	177
96	Presumptive Type 1 Diabetes With Comorbidities and Rapid Progression Despite Numerous Insulin-Positive Islets. Diabetes Care, 2016, 39, 1292-1294.	8.6	3
97	HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. Diabetes, 2016, 65, 1109-1119.	0.6	48
98	The influence of type 1 diabetes on pancreatic weight. Diabetologia, 2016, 59, 217-221.	6.3	88
99	Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1826-34.	7.1	492
100	Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care, 2016, 39, 555-562.	8.6	91
101	Insulitis and Î²-Cell Mass in the Natural History of Type 1 Diabetes. Diabetes, 2016, 65, 719-731.	0.6	292
102	Effects of Gluten Intake on Risk of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort. Clinical Gastroenterology and Hepatology, 2016, 14, 403-409.e3.	4.4	102
103	Puppy Love, Adolescence, and Chronic Illness: The Importance of Pets for Youth with Type 1 Diabetes. Journal of Patient Experience, 2015, 2, 21-24.	0.9	3
104	Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. Diabetes Care, 2015, 38, 1975-1985.	8.6	68
105	Lowering targets for hemoglobin A1c in children with type 1 diabetes: raising the bar. Pediatric Diabetes, 2015, 16, 16-21.	2.9	4
106	Using Photography as a Method to Explore Adolescent Challenges and Resilience in Type 1 Diabetes. Diabetes Spectrum, 2015, 28, 92-98.	1.0	8
107	Screening for T1D risk to reduce DKA is not economically viable. Pediatric Diabetes, 2015, 16, 565-572.	2.9	25
108	The 6Âyear incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia, 2015, 58, 980-987.	6.3	313

#	Article	IF	Citations
109	Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care, 2015, 38, 808-813.	8.6	135
110	Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes. Diabetes, 2015, 64, 3873-3884.	0.6	22
111	Disparities in Social Support Systems for Youths With Type 1 Diabetes. Clinical Diabetes, 2015, 33, 62-69.	2.2	17
112	Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the UnitedÂStates. Journal of Pediatrics, 2015, 167, 627-632.e4.	1.8	150
113	Body Mass Index Changes in Youth in the First Year after Type 1 Diabetes Diagnosis. Journal of Pediatrics, 2015, 166, 1265-1269.e1.	1.8	15
114	Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015, 38, 1964-1974.	8.6	690
115	Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes. Diabetes, 2015, 64, 3885-3890.	0.6	42
116	Role of Type 1 Diabetesâ€“Associated SNPs on Risk of Autoantibody Positivity in the TEDDY Study. Diabetes, 2015, 64, 1818-1829.	0.6	108
117	Early Childhood Gut Microbiomes Show Strong Geographic Differences Among Subjects at High Risk for Type 1 Diabetes. Diabetes Care, 2015, 38, 329-332.	8.6	79
118	Anti-thymocyte globulin/G-CSF treatment preserves Î² cell function in patients with established type 1 diabetes. Journal of Clinical Investigation, 2015, 125, 448-455.	8.2	140
119	Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes. Diabetes Care, 2014, 37, 1959-1965.	8.6	6
120	Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. Frontiers in Microbiology, 2014, 5, 678.	3.5	241
121	The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes () Tj ETQq1 1 0.784314 rgBT /Overlock 15, 1-9.	2.9	139
122	B-Lymphocyte Depletion With Rituximab and Î²-Cell Function: Two-Year Results. Diabetes Care, 2014, 37, 453-459.	8.6	210
123	Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment. Diabetes Care, 2014, 37, 1069-1075.	8.6	168
124	Compromised Gut Microbiota Networks in Children With Anti-Islet Cell Autoimmunity. Diabetes, 2014, 63, 2006-2014.	0.6	154
125	Healthcare Transition from Pediatric to Adult Medical Homes. Endocrine Practice, 2014, 20, 714-720.	2.1	4
126	9Î² Polymorphism of the Glucocorticoid Receptor Gene Appears to Have Limited Impact in Patients with Addisonâ€™s Disease. PLoS ONE, 2014, 9, e86350.	2.5	4

#	Article	IF	Citations
127	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, The, 2013, 381, 1905-1915.	13.7	301
128	Framing Food and Diabetes. ICAN: Infant, Child, & Adolescent Nutrition, 2013, 5, 347-355.	0.2	2
129	Increased Complement Activation in Human Type 1 Diabetes Pancreata. Diabetes Care, 2013, 36, 3815-3817.	8.6	44
130	Performance of HbA1c as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. Diabetes Care, 2012, 35, 1821-1825.	8.6	39
131	Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2012, 28, 608-617.	4.0	178
132	Through the Fog: Recent Clinical Trials to Preserve Î²-Cell Function in Type 1 Diabetes. Diabetes, 2012, 61, 1323-1330.	0.6	37
133	The Thyroid. , 2012, , 1905-1944.		3
134	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2011, 378, 412-419.	13.7	493
135	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet, The, 2011, 378, 319-327.	13.7	325
136	Toward defining the autoimmune microbiome for type 1 diabetes. ISME Journal, 2011, 5, 82-91.	9.8	709
137	Long-Term Outcome of Individuals Treated With Oral Insulin. Diabetes Care, 2011, 34, 1585-1590.	8.6	108
138	It's Time to Mow the GRAS in Type 1 Diabetes: FIG. 1.. Diabetes, 2011, 60, 2669-2671.	0.6	3
139	Autoimmune Markers in Diabetes. Clinical Chemistry, 2011, 57, 168-175.	3.2	110
140	Islet Autoantibody Seroconversion in the DPT-1 Study. Diabetes Care, 2011, 34, 358-362.	8.6	18
141	Development of Autoantibodies in the TrialNet Natural History Study. Diabetes Care, 2011, 34, 1897-1901.	8.6	55
142	Enhancing the Understanding of Pre-Type 1 Diabetes in the General Population. Diabetes Care, 2010, 33, 1403-1405.	8.6	7
143	Harmonization of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3360-3367.	3.6	244
144	Preface. Endocrinology and Metabolism Clinics of North America, 2010, 39, xvii-xviii.	3.2	1

#	Article	IF	Citations
145	Efforts to Prevent and Halt Autoimmune Beta Cell Destruction. Endocrinology and Metabolism Clinics of North America, 2010, 39, 527-539.	3.2	10
146	Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trialâ€“Type 1. Diabetes Care, 2009, 32, 2269-2274.	8.6	224
147	Immune Depletion With Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice. Diabetes, 2009, 58, 2277-2284.	0.6	68
148	Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes/Metabolism Research and Reviews, 2009, 25, 694-704.	4.0	19
149	Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. New England Journal of Medicine, 2009, 361, 2143-2152.	27.0	900
150	Whatâ€™s in a name? Thyroid autoimmunity in obese patients with T1D. Pediatric Diabetes, 2008, 9, 263-265.	2.9	1
151	Type 1 diabetes intervention trials 2007: where are we and where are we going?. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 283-287.	2.3	30
152	Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatric Diabetes, 2007, 8, 193-198.	2.9	119
153	Specific Human Leukocyte Antigen DQ Influence on Expression of Antiislet Autoantibodies and Progression to Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1705-1713.	3.6	32
154	Maternal understanding of infant diabetes risk: Differential effects of maternal anxiety and depression. Genetics in Medicine, 2006, 8, 665-670.	2.4	19
155	Islet cell autoantibodies: a case of a premature obituary. Pediatric Diabetes, 2005, 6, 181-183.	2.9	6
156	Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. Journal of Autoimmune Diseases, 2005, 2, 8.	1.0	46
157	Maternal Anxiety Associated With Newborn Genetic Screening for Type 1 Diabetes. Diabetes Care, 2004, 27, 392-397.	8.6	43
158	Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus - a new surrogate measure of non-progression?. Pediatric Diabetes, 2004, 5, 72-79.	2.9	35
159	Oral Insulin Therapy to Prevent Progression of Immune-Mediated (Type 1) Diabetes. Annals of the New York Academy of Sciences, 2004, 1029, 260-277.	3.8	54
160	Diabetes, Type 1. , 2004, , 666-670.		0
161	Overview of prevention and intervention trials for type 1 diabetes. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 317-323.	5.7	23
162	Why Can't We Prevent Type 1 Diabetes?: Maybe it's time to try a different combination. Diabetes Care, 2003, 26, 3326-3328.	8.6	31

#	Article	IF	Citations
163	Screening Strategies for the Identification of Multiple Antibody-Positive Relatives of Individuals with Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 103-108.	3.6	116
164	Prospective assessment in newborns of diabetes autoimmunity (PANDA): Maternal understanding of infant diabetes risk. Genetics in Medicine, 2003, 5, 77-83.	2.4	43
165	To Screen or Not to Screen for Pre-TypeÂ1 Diabetes?. Hormone Research in Paediatrics, 2002, 57, 12-17.	1.8	8
166	Autoimmune polyglandular syndrome II: clinical syndrome and treatment. Endocrinology and Metabolism Clinics of North America, 2002, 31, 339-352.	3.2	78
167	Prediction and prevention of type 1 diabetes. Current Diabetes Reports, 2001, 1, 28-32.	4.2	10
168	Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nature Medicine, 2000, 6, 278-282.	30.7	675
169	Only Multiple Autoantibodies to Islet Cells (ICA), Insulin, GAD65, IA-2 and IA-2Î² Predict Immune-Mediated (Type 1) Diabetes in Relatives. Journal of Autoimmunity, 1999, 12, 279-287.	6.5	103
170	Extreme Th1 bias of invariant VÎ±24JÎ±Q T cells in type 1 diabetes. Nature, 1998, 391, 177-181.	27.8	639
171	Patient and Family Reflections on the Use of Subcutaneous Insulin to Prevent Diabetes. Journal of Diabetes and Its Complications, 1998, 12, 279-286.	2.3	16
172	Neonatal prevention of IDDM?. Diabetes/metabolism Reviews, 1998, 14, 106-107.	0.3	1
173	Pharmacological Approaches to the Prevention of Autoimmune Diabetes. Drugs, 1997, 53, 943-956.	10.9	6
174	Antigenâ€specific immunotherapy: Oral tolerance and subcutaneous immunization in the treatment of insulinâ€dependent diabetes. Diabetes/metabolism Reviews, 1993, 9, 279-287.	0.3	28
175	Intervention Therapies for Insulin-Dependent Diabetes. Autoimmunity, 1993, 16, 301-310.	2.6	6
176	A Prospective Study of the Development of Diabetes in Relatives of Patients with Insulin-Dependent Diabetes. New England Journal of Medicine, 1990, 323, 1167-1172.	27.0	290
177	Relationship of autoimmunity to thyroid dysfunction in children and adults with Down syndrome. American Journal of Medical Genetics Part A, 1990, 37, 238-241.	2.4	29
178	Long-Term Immunoregulatory Effects of Therapy with Corticosteroids and Anti-Thymocyte Globulin. Immunopharmacology and Immunotoxicology, 1989, 11, 269-287.	2.4	6
179	Natural history of incidental hyperglycemia and glycosuria of childhood. Journal of Pediatrics, 1989, 115, 676-680.	1.8	38
180	Polyclonal Nature of Islet Cell Antibodies in Insulin-Dependent Diabetes. Autoimmunity, 1988, 1, 45-50.	2.6	23